FDA Opens Potential Single-Trial Pathway for Neurizon’s ALS Therapy

FDA Identifies Potential Single-Trial Approval Route

Neurizon Therapeutics Limited (ASX:NUZ) has received a regulatory signal that could materially simplify the path for its experimental ALS therapy, although the decisive test remains ahead. The US Food and Drug Administration said positive results from the Phase 2/3 HEALEY ALS Platform Trial could potentially support a traditional approval for NUZ-001.

More significantly, the FDA said the trial may serve as the single registrational study for a New Drug Application. That possibility is subject to the study producing substantial evidence of effectiveness, alongside supporting evidence. It is guidance on a potential pathway, not an approval decision or a guarantee that an NDA would be accepted.

Regimen I Moves Towards the Decisive Readout

NUZ-001 is being tested as Regimen I in the HEALEY platform, a double-blind, placebo-controlled Phase 2/3 study designed to assess clinically meaningful endpoints after 36 weeks of treatment. The regimen is fully enrolled and remains on track for topline results in late Q2 2027, placing the trial outcome at the centre of Neurizon’s regulatory strategy.

The enrolment milestone follows the company’s placeholder and is the point at which the FDA’s conditional guidance becomes most consequential: the potential single-study pathway only has practical value if the primary clinical evidence is persuasive. Neurizon has said it is preparing an evidence package for a traditional-approval NDA, with biomarker results intended to provide additional support.

NfL Evidence Could Support the Submission

The FDA agreed with Neurizon’s approach to measuring plasma neurofilament light chain, or NfL, a marker of nerve damage. The agency outlined the evidence that would be needed for NfL to support an accelerated-approval route, while Neurizon remains focused on traditional approval rather than relying on that alternative.

The distinction matters. If the HEALEY primary endpoint is not met, the company would need a strong scientific rationale for any reliance on biomarker evidence. The filing therefore leaves open a potentially useful supporting role for NfL, but does not suggest that biomarker data could substitute straightforwardly for clinical efficacy.

Expanded Access Adds Longer-Term Data

An NIH-funded expanded access program is expected to begin in Q1 2027 and provide NUZ-001 to approximately 200 people with ALS in the United States for up to 96 weeks. The program follows the NIH expanded access grant, which was intended to extend access to patients outside the pivotal trial while generating longer-term safety and biomarker information.

Neurizon is also evaluating whether to resubmit a Fast Track Designation request after the FDA declined its January 2026 application. Any resubmission would be assessed on the data available at that time. Until then, the key catalyst is less procedural: whether Regimen I can deliver the positive, clinically meaningful result needed to turn a possible regulatory route into a credible NDA strategy.